Back | Next |
home / stock / edit / edit message board
Subject | By | Source | When |
---|---|---|---|
New preclinical data https://www.nature.com/articles/s41467-021-24017-8 | jondoeuk | investorshub | 08/01/2021 1:16:46 AM |
znewcar1: EDIT 22% v15M c56.64 f67,8M H58.47 | znewcar1 | investorshangout | 06/30/2021 10:16:41 PM |
Not sure what happened in the last hour, | Gpheart2016 | investorshub | 06/30/2021 3:36:29 PM |
For sure! I've been in$ NTLA, $EDIT | go_glortho | investorshub | 06/28/2021 9:37:10 PM |
Here we go! Gene editing stocks will | Gpheart2016 | investorshub | 06/28/2021 1:12:01 PM |
Ouch...LoL | Cat | investorshub | 04/12/2021 8:58:49 PM |
$EDIT has had a huge sell-off but should | Gpheart2016 | investorshub | 03/04/2021 7:33:09 PM |
News out today ubx | Kwl1 | investorshub | 02/08/2021 1:57:22 PM |
Added 2000 shares at 70.80 & 70.90 | Fress | investorshub | 01/20/2021 9:25:12 PM |
Genome Stocks-Gene Editing. | Fress | investorshub | 01/07/2021 3:25:05 PM |
edit Looking for a $100.00 floor soon this | Fress | investorshub | 12/29/2020 1:34:23 PM |
* * $EDIT Video Chart 12-21-2020 * * | ClayTrader | investorshub | 12/21/2020 10:45:21 PM |
znewcar1: EDIT 29% v10,3M c83.66 f62,3M H96.45 S83.7 | znewcar1 | investorshangout | 12/21/2020 9:37:15 PM |
Yes, no sympathy for the short sellers, but | Gpheart2016 | investorshub | 12/21/2020 5:27:52 PM |
Good call on the Short Squeeze. I've | go_glortho | investorshub | 12/21/2020 4:45:59 PM |
CRSPR stocks are hot indeed! This continued | Gpheart2016 | investorshub | 12/21/2020 3:42:34 PM |
Let's just say the$ CRSPR sector is hot! | MWM | investorshub | 12/11/2020 10:32:41 AM |
znewcar1: EDIT 32% v9,6M c66.84 f62,3M H67.27 | znewcar1 | investorshangout | 12/10/2020 9:55:12 PM |
* * $EDIT Video Chart 12-10-2020 * * | ClayTrader | investorshub | 12/10/2020 9:44:29 PM |
It looks like $EDIT has become stock of | Gpheart2016 | investorshub | 12/10/2020 8:20:40 PM |
News, Short Squeeze, Breakout and More Instantly...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...